Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 13/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761551 | 0.86 | MAP2K2 (0.44) | MAP2K2MAP2K1ALDH1A1MAPK1USP2 | |
| SCHEMBL3760601 | 0.86 | MAP2K2 (0.56) | MAP2K2MAP2K1ALDH1A1MAPK1USP2 | |
| SCHEMBL3764678 | 0.79 | MAP2K2 (0.49) | MAP2K2MAP2K1ALDH1A1MAPK1USP2 | |
| SCHEMBL4019351 | 0.74 | MAP2K2 (1.00) | MAP2K2MAP2K1 | |
| SCHEMBL4084302 | 0.73 | MAP2K2 (0.80) | MAP2K2MAP2K1ALDH1A1MAPK1USP2 | |
| SCHEMBL4512535 | 0.73 | MAP2K2 (0.79) | MAP2K2MAP2K1ALDH1A1MAPK1USP2 | |
| SCHEMBL3760020 | 0.72 | ALDH1A1 (0.51) | MAP2K2MAP2K1ALDH1A1MAPK1TDP1 | |
| SCHEMBL4503267 | 0.72 | MAP2K2 (1.00) | MAP2K2MAP2K1ALDH1A1MAPK1USP2 | |
| SCHEMBL3765154 | 0.70 | ALDH1A1 (0.62) | ALDH1A1MAPK1USP2HTTTDP1 | |
| SCHEMBL4508634 | 0.70 | MAP2K2 (0.78) | MAP2K2MAP2K1ALDH1A1MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | MAP2K2 44/4885MAP2K1 87/4885ALDH1A1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.